Applera Corporation Announces Second HIV/AIDS Treatment Site

SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has added a second HIV/AIDS clinical study location at the Bhvani Hospital in Bihar, India. Aethlon previously disclosed plans to initiate the “first-in-man” clinical study of a medical device to treat the Human Immunodeficiency Virus (HIV), which causes Acquired Immune Deficiency Syndrome (AIDS). The Aethlon Hemopurifier® is a medical device created to provide real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. The Hemopurifier® holds promise to extend the lives of AIDS patients by removing HIV strains that cause drug failure and reducing the presence of viral proteins that kill-off immune cells. On June 24th, Aethlon announced that its first HIV/AIDS treatment study had been approved by the Institutional Ethics Committee at Jattinder Gambhir Hospital (J.G. Hospital) in Punjab, India. Clinical studies at both site locations are anticipated to begin in September.